Clinical Trials Directory

Trials / Completed

CompletedNCT06072508

Prognostic Interest of Vasorin in Septic Shock

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Centre Hospitalier Universitaire, Amiens · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In septic shock, the intensity and duration of low blood pressure can lead to a critical reduction in renal tissue perfusion and lead to the onset of more or less severe Acute Kidney Injury (AKI). Vasorin (Vasn) is a protein strongly expressed in large vessels and kidneys, whose functions are still poorly known. Previous experimental studies show that Vasn is associated with decreased Angiotensin II concentrations, a vessel contractility defect and early mortality. The investigators hypothesize that Vasn (the potential direct regulator of blood pressure) would be an early biomarker predicting the severity of AKI post septic shock, which may be associated with mortality from septic shock or lead to longer-term Chronic Renal Failure (CKD).

Conditions

Interventions

TypeNameDescription
BIOLOGICALBlood samplingBlood sampling (at day 0 and day 3) for Vasn, Angiotensin 2 and clotting markers.

Timeline

Start date
2023-07-03
Primary completion
2025-03-29
Completion
2025-03-29
First posted
2023-10-10
Last updated
2026-03-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06072508. Inclusion in this directory is not an endorsement.